Posted by Colin Rose on July 9, 2008
Here is a good example of a “study” of statins written by a non-medically licenced employee of a statin-peddling drug company, Merck Frosst Schering, with the names of prominent “experts”, many known to be financially associated with drug companies, shown as secondary authors.
What a nice name! Reminds one of sunny Caribbean islands. Except they had to use an “I” instead of a “y”. Guess they couldn’t find an acronym that fit easily. What was done? Doctors were paid to collect data on patients to whom they prescribed statins. Results? Horrors of horrors, many of them did not reach “target” LDL (bad blood cholesterol). Conclusion? You guessed it. Not enough people are taking enough statins. Suggestion? “Strategies should be implemented to promote achievement of lipid treatment goals…”
Who sets these “targets” anyway? Again, you guessed it, the same sort of doctors as the authors listed in CALIPSO, most paid by drug dealers in one way or another. See the evidence in the US and Canada.
More than half of the subjects had no history of cardiovascular disease, so statins were being used for primary prevention and there is no overall benefit of statins this class of patient.
Note that the first author is employed by a Merck, a big seller of statins.
No attempt was made to alter high risk lifestyles (42% had abdominal obesity and 17% smoked). That’s hard work and takes a lot of time. But, why bother? Surely, after years of medical terrorism by drug dealers, everyone knows that atherosclerosis is caused by bad blood cholesterol and there is a very profitable strategy for attaining “lipid treatment goals”; pay doctors to give statins to reach those arbitrary targets as is now happening in parts of the USA.
The Canadian Journal of Cardiololgy, at least 80% of whose revenue comes from drug companies, does not require financial disclosure by authors but we have found them from another source. In the Acknowledgements those nice people at Merck and BioMedCom, contracted to do the “study”, are thanked.
While BioMedCom claims to do “scientifically rigorous” work, CALIPSO is not science at all. It is a highly biased sample of what doctors will do if paid to report on the patients to whom they prescibe statins. There is no proof that if the patients had reached “target” they would have benefitted at all. There is no control group who did not receive statins and there is no indication of outcome at all. This is not science, but another attempt at medical terrorism to sell more drugs and any doctor who would put his name on such a study cannot claim to be an expert in “hypercholesterolemia” nor should he or she be part of any group advising other doctors like the “Working Group” in Canada.
Why would all those “experts” in the author list need to hire BioMedCom, to do this “study”? What did these doctors do to justify putting their names on the “study”? And why is an employee of Merck first author? We leave the answers to the reader’s imagination.
Financial Conflicts of Interest Not Reported in CALIPSO Paper